JRJoyce Rauch

Joyce Rauch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joyce Rauch has a total of 117 co-authors. Here are the top co-authors by number of shared publications:

  • Jerrold S. Levine

    Section of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States

    11 shared publications
  • Rebecca Subang

    Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec, Canada

    10 shared publications
  • David Salem

    Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec, Canada

    5 shared publications
  • Jerrold S. Levine

    Section of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA

    3 shared publications
  • Js Levine

    Section of Nephrology, Department of Medicine, University of Illinois at Chicago, and Section of Nephrology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, USA

    3 shared publications
  • Masataka Kuwana

    Department of Allergy and Rheumatology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan

    3 shared publications

Latest Publications

  • Open Access

    Serum perfluorooctane sulfonate and perfluorooctanoic acid concentrations and longitudinal systemic lupus outcomes

    by Naizhuo Zhao, Adam Rochepeau, Sébastien Sauvé, Arielle Mendel, Evelyne Vinet, Marc-André Verner, Joyce Rauch, Christian A. Pineau, Luck Lukasa, Louis-Pierre Grenier, et al.

  • Open Access

    Type I interferon-dependent and -independent signaling underlie autoantibody production in a murine lupus model

    by Jerrold S. Levine, Céleste Pilon, Rebecca Subang, David Salem, Elena Lonina, Salman T. Qureshi, Gregory J. Fonseca, Philippe Gros, Joyce Rauch


  • Open Access

    RIPK3 impacts antibody generation in an induced model of murine lupus through mechanisms other than necroptosis and antigen presentation

    by Céleste Pilon, Elena Lonina, Jerrold S. Levine, Sylvie Lesage, Joyce Rauch

    Introduction: Receptor-interacting protein kinase 3 (RIPK3) is a protein involved in cell death and inflammatory processes. The most recognized function of RIPK3 is the induction of necroptosis, an inflammatory type of cell death that is dependent on RIPK3 kinase activity. Deficiency in RIPK3-dependent pathways has been associated with protection from various inflammatory and autoimmune conditions. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the generation of autoantibodies to multiple intracellular antigens leading to multi-organ pathology. Little is known about the involvement of RIPK3-dependent pathways in SLE. We have previously shown that autoantibody generation in an induced model of murine lupus is impaired in RIPK3-deficient mice. The current study aimed to identify the RIPK3-dependent mechanisms that contribute to autoantibody generation in this induced model of murine lupus.Methods: SLE was induced in C57BL/6 (wild type), RIPK3-/-, RIPK3K51A/K51A, and MLKL-/- mice by subcutaneous immunization with a mixture of β2-glycoprotein I and lipopolysaccharide in order to evaluate the contribution of RIPK3 and MLKL to autoantibody production in this model. Bone marrow chimeras were generated to investigate the impact of RIPK3 deficiency within the hematopoietic compartment. Antigen presentation assays assessed the impact of RIPK3 deficiency in antigen presenting cells on T cell activation in vitro. T cells were evaluated ex vivo by flow cytometry following the induction of SLE in wild type and RIPK3-dependent pathway-deficient mice.Results: Generation of autoantibodies to SLE antigens following immunization with β2-glycoprotein I and lipopolysaccharide was found to be dependent on RIPK3 activity, but independent of MLKL (i.e., RIPK3-dependent necroptosis). Bone marrow chimeric experiments revealed that RIPK3 mediates autoantibody generation through both immune and non-immune compartments. RIPK3 deficiency within antigen presenting cells did not impact T cell activation in vitro. Moreover, early and late T cell activation ex vivo was not impaired in RIPK3-deficient mice following induction of murine lupus.Conclusion: These results suggest that RIPK3 contributes to autoantibody generation in our induced model of murine lupus through an interplay of pathways that appear to be independent of necroptosis and antigen presentation.


  • Open Access

    Vascular injury derived apoptotic exosome-like vesicles trigger autoimmunity

    by Sandrine Juillard, Annie Karakeussian-Rimbaud, Marie-Hélène Normand, Julie Turgeon, Charlotte Veilleux-Trinh, Alexa C. Robitaille, Joyce Rauch, Andrzej Chruscinski, Nathalie Grandvaux, Éric Boilard, et al.


  • Open Access

    Characterization and use of the ECV304 autoantigenic citrullinome to understand anti-citrullinated protein/peptide autoantibodies in rheumatoid arthritis

    by Natalia Regine de França, Henri André Ménard, Maximilien Lora, Zhijie Zhou, Joyce Rauch, Carol Hitchon, Luís Eduardo Coelho Andrade, Inés Colmegna

    Background: Anti-citrullinated protein antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA). In vivo, ACPAs target peptidyl-citrulline epitopes (cit-) in a variety of proteins (cit-prot-ACPAs) and derived peptides (cit-pept-ACPAs) generated via the peptidylarginine deiminase (PAD) isoenzymes. We aimed to identify a cell line with self-citrullination capacity, to describe its autoantigenic citrullinome, and to test it as a source of autocitrullinated proteins and peptides. Methods: Human cell lines were screened for cit-proteins by Western blot. PAD isoenzymes were identified by RT-PCR. Autocitrullination of ECV304 was optimized, and the ECV304 autocitrullinomes immunoprecipitated by sera from three RA patients were characterized by mass spectrometry. Cit-pept-ACPAs were detected using anti-CCP2 ELISA and cit-prot-ACPAs, by an auto-cit-prot-ECV304 ELISA. Sera from 177 RA patients, 59 non-RA rheumatic disease patients and 25 non-disease controls were tested. Results: Of the seven cell lines studied, only ECV304 simultaneously overexpressed PAD2 and PAD3 and its extracts reproducibly autocitrullinated self and non-self-proteins. Proteomic analysis of the cit-ECV304 products immunoprecipitated by RA sera, identified novel cit-targets: calreticulin, profilin 1, vinculin, new 14–3-3 protein family members, chaperones, and mitochondrial enzymes. The auto-cit-prot-ECV304 ELISA had a sensitivity of 50% and a specificity of 95% for RA diagnosis. Conclusions: ECV304 cells overexpress two of the PAD isoenzymes capable of citrullinating self-proteins. These autocitrullinated cells constitute a basic and clinical research tool that enable the detection of cit-prot-ACPAs with high diagnostic specificity and allow the identification of the specific cit-proteins targeted by individual RA sera.


  • Necroptotic cell binding of β2‐glycoprotein I provides a potential autoantigenic stimulus in systemic lupus erythematosus

    by David Salem, Rebecca Subang, Erwan Pernet, Maziar Divangahi, Christian Pineau, Romain Cayrol, Jerrold S. Levine, Joyce Rauch

    Systemic lupus erythematosus (SLE) is characterized by the development of autoantibodies against diverse self‐antigens with damage to multiple organs. Immunization with the SLE autoantigen β2‐glycoprotein I (β2GPI) and lipopolysaccharide (LPS), a known trigger of necroptosis, induces a murine model of SLE. We hypothesized that necroptotic cells, like apoptotic cells, provide a “scaffold” of cellular self‐antigens, but, unlike apoptotic cells, necroptotic cells do so in a proinflammatory and immunogenic context. We demonstrate that β2GPI indeed binds to necroptotic cells and serves as a target for anti‐β2GPI autoantibodies. We further demonstrate that necroptotic, but not apoptotic, cells promote antigenic presentation of β2GPI to CD4 T cells by dendritic cells. Finally, we show that β2GPI/LPS‐immunized mice deficient in RIPK3 (receptor‐interacting serine/threonine‐protein kinase 3) or MLKL (mixed lineage kinase domain like), and consequently unable to undergo necroptosis, have reduced SLE autoantibody production and pathology. RIPK3−/− mice had low levels of SLE autoantibodies and no renal pathology, while MLKL−/− mice produced low levels of SLE autoantibodies initially, but later developed levels comparable with wild type (WT) mice and pathology intermediate to that of WT and RIPK3−/− mice. Serum cytokine levels induced by LPS tended to be lower in RIPK3−/− and MLKL−/− mice than in WT mice, suggesting that impaired proinflammatory cytokine production may impact the initiation of autoantibody production in both strains. Our data suggest that self‐antigen (i.e. β2GPI) presented in the context of necroptosis and proinflammatory signals may be sufficient to overcome immune tolerance and induce SLE.


  • Open Access

    β2-Glycoprotein I-Reactive T Cells in Autoimmune Disease

    by Joyce Rauch, David Salem, Rebecca Subang, Masataka Kuwana, Jerrold S. Levine

    Anti-phospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are autoimmune diseases characterized by autoantibody production and autoantibody-related pathology. Anti-phospholipid antibodies (aPL) are found in all patients with APS and in 20–30% of individuals with SLE. aPL recognize a number of autoantigens, but the primary target in both APS and SLE is β2-glycoprotein I (β2GPI). The production of IgG aPL in APS and SLE, as well as the association of aPL with certain MHC class II molecules, has led to investigation of the role of β2GPI-reactive T helper (Th). β2GPI-reactive CD4 Th cells have been associated with the presence of aPL and/or APS in both primary APS and secondary APS associated with SLE, as well as in SLE patients and healthy controls lacking aPL. CD4 T cells reactive with β2GPI have also been associated with atherosclerosis and found within atherosclerotic plaques. In most cases, the epitopes targeted by autoreactive β2GPI-reactive CD4 T cells in APS and SLE appear to arise as a consequence of antigenic processing of β2GPI that is structurally different from the soluble native form. This may arise from molecular interactions (e.g., with phospholipids), post-translational modification (e.g., oxidation or glycation), genetic alteration (e.g., β2GPI variants), or molecular mimicry (e.g., microbiota). A number of T cell epitopes have been characterized, particularly in Domain V, the lipid-binding domain of β2GPI. Possible sources of negatively charged lipid that bind β2GPI include oxidized LDL, activated platelets, microbiota (e.g., gut commensals), and dying (e.g., apoptotic) cells. Apoptotic cells not only bind β2GPI, but also express multiple other cellular autoantigens targeted in both APS and SLE. Dying cells that have bound β2GPI thus provide a rich source of autoantigens that can be recognized by B cells across a wide range of autoantigen specificities. β2GPI-reactive T cells could potentially provide T cell help to autoantigen-specific B cells that have taken up and processed apoptotic (or other dying) cells, and subsequently present β2GPI on their surface in the context of major histocompatibility complex (MHC) class II molecules. Here, we review the literature on β2GPI-reactive T cells, and highlight findings supporting the hypothesis that these T cells drive autoantibody production in both APS and SLE.


  • T cells from induced and spontaneous models of SLE recognize a common T cell epitope on β2-glycoprotein I

    by David Salem, Rebecca Subang, Masataka Kuwana, Jerrold S. Levine, Joyce Rauch

    Systemic lupus erythematosus is a prototypic model for B-cell epitope spread in autoimmunity. Autoantibodies to numerous molecularly distinct self-antigens emerge in a sequential manner over several years, leading to disease manifestations. Among the earliest autoantibodies to appear are those targeting phospholipid-binding proteins, particularly β2-glycoprotein I. Notably, mice immunized with β2-glycoprotein I and lipopolysaccharide develop a strong T cell response to β2-glycoprotein I that is associated with autoantibody production and renal disease, similar to that seen in human SLE. Here we hypothesized that mice with murine systemic lupus erythematosus, whether induced or spontaneous, should have T cells that recognize β2-glycoprotein I. We evaluated the response of splenic T cells from mice with induced (C57BL/6 and C3H/HeN) and spontaneous (MRL/lpr) systemic lupus erythematosus to peptides spanning the entire sequence of human β2GPI. We found that mice with induced and spontaneous systemic lupus erythematosus recognize a common T cell epitope (peptide 31; LYRDTAVFECLPQHAMFG) in domain III of β2-glycoprotein I. β2GPI-reactive CD4+ T cells from the two models differed primarily in cytokine production: T cells from mice with induced SLE expressed IFN-γ, while T cells from MRL/lpr mice expressed both IL-17 and IFN-γ, indicating that IL-17-expressing T cells are not necessary for generating a β2GPI-reactive T cell response. These data suggest that the generation of a β2-glycoprotein I-reactive T cell response is shared by both induced and spontaneous models of systemic lupus erythematosus and that this T cell response may mediate epitope spread to autoantibodies in both models.


  • Origin of Antiphospholipid Antibodies

    by Joyce Rauch, Miri Blank, Philip G. de Groot, Kathryn M. Dupnik, Martin Alexander Kriegel, Jerrold S. Levine, Yehuda Shoenfeld, Rohan Willis


  • Antiphospholipid antibody-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4

    by P Laplante, R Fuentes, D Salem, R Subang, M-A Gillis, A Hachem, N Farhat, S T Qureshi, C A Fletcher, R A S Roubey, et al.

    Patients with antiphospholipid syndrome (APS) produce antiphospholipid antibodies (aPL) and develop vascular thrombosis that may occur in large or small vessels in the arterial or venous beds. On the other hand, many individuals produce aPL and yet never develop thrombotic events. Toll-like receptor 4 (TLR4) appears to be necessary for aPL-mediated prothrombotic effects in venous and microvascular models of thrombosis, but its role in arterial thrombosis has not been studied. Here, we propose that aPL alone are insufficient to cause thrombotic events in an arterial model of APS, and that a concomitant trigger of innate immunity (e.g. TLR4 activation) is required. We show specifically that anti-β2-glycoprotein I (anti-β2GPI) antibodies, a subset of aPL, accelerated thrombus formation in C57BL/6 wild-type, but not TLR4-deficient, mice in a ferric chloride-induced carotid artery injury model. These aPL bound to arterial and venous endothelial cells, particularly in the presence of β2GPI, and to human TLR4 by enzyme-linked immunoassay. Arterial endothelium from aPL-treated mice had enhanced leukocyte adhesion, compared to control IgG-treated mice. In addition, aPL treatment of mice enhanced expression of tissue factor (TF) in leukocytes induced by the TLR4 ligand lipopolysaccharide (LPS). aPL also enhanced LPS-induced TF expression in human leukocytes in vitro. Our findings support a mechanism in which aPL enhance TF expression by leukocytes, as well as augment adhesion of leukocytes to the arterial endothelium. The activation of TLR4 in aPL-positive individuals may be required to trigger thrombotic events.